- Home
- SGA vs ARMP Comparison
SGA vs ARMP Comparison
Compare SGA & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGA
- ARMP
- Stock Information
- Founded
- SGA 1986
- ARMP N/A
- Country
- SGA United States
- ARMP United States
- Employees
- SGA N/A
- ARMP N/A
- Industry
- SGA Broadcasting
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGA Consumer Discretionary
- ARMP Health Care
- Exchange
- SGA Nasdaq
- ARMP Nasdaq
- Market Cap
- SGA 84.1M
- ARMP 92.4M
- IPO Year
- SGA 1992
- ARMP N/A
- Fundamental
- Price
- SGA $13.30
- ARMP $2.50
- Analyst Decision
- SGA
- ARMP Strong Buy
- Analyst Count
- SGA 0
- ARMP 1
- Target Price
- SGA N/A
- ARMP $9.00
- AVG Volume (30 Days)
- SGA 4.4K
- ARMP 8.8K
- Earning Date
- SGA 08-07-2025
- ARMP 08-12-2025
- Dividend Yield
- SGA 7.57%
- ARMP N/A
- EPS Growth
- SGA N/A
- ARMP N/A
- EPS
- SGA 0.33
- ARMP N/A
- Revenue
- SGA $110,350,000.00
- ARMP $6,868,000.00
- Revenue This Year
- SGA N/A
- ARMP $8.43
- Revenue Next Year
- SGA $4.84
- ARMP N/A
- P/E Ratio
- SGA $40.33
- ARMP N/A
- Revenue Growth
- SGA N/A
- ARMP 84.67
- 52 Week Low
- SGA $10.75
- ARMP $0.90
- 52 Week High
- SGA $15.58
- ARMP $2.96
- Technical
- Relative Strength Index (RSI)
- SGA 54.68
- ARMP 54.27
- Support Level
- SGA $12.10
- ARMP $2.39
- Resistance Level
- SGA $13.51
- ARMP $2.72
- Average True Range (ATR)
- SGA 0.43
- ARMP 0.17
- MACD
- SGA 0.04
- ARMP -0.01
- Stochastic Oscillator
- SGA 85.11
- ARMP 39.17
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.